1. Home
  2. ARDX vs COLL Comparison

ARDX vs COLL Comparison

Compare ARDX & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ARDX
  • COLL
  • Stock Information
  • Founded
  • ARDX 2007
  • COLL 2002
  • Country
  • ARDX United States
  • COLL United States
  • Employees
  • ARDX N/A
  • COLL N/A
  • Industry
  • ARDX Biotechnology: Pharmaceutical Preparations
  • COLL Biotechnology: Pharmaceutical Preparations
  • Sector
  • ARDX Health Care
  • COLL Health Care
  • Exchange
  • ARDX Nasdaq
  • COLL Nasdaq
  • Market Cap
  • ARDX 882.9M
  • COLL 958.8M
  • IPO Year
  • ARDX 2014
  • COLL 2015
  • Fundamental
  • Price
  • ARDX $4.32
  • COLL $30.35
  • Analyst Decision
  • ARDX Strong Buy
  • COLL Strong Buy
  • Analyst Count
  • ARDX 9
  • COLL 4
  • Target Price
  • ARDX $10.17
  • COLL $43.75
  • AVG Volume (30 Days)
  • ARDX 4.6M
  • COLL 289.9K
  • Earning Date
  • ARDX 07-31-2025
  • COLL 08-07-2025
  • Dividend Yield
  • ARDX N/A
  • COLL N/A
  • EPS Growth
  • ARDX N/A
  • COLL N/A
  • EPS
  • ARDX N/A
  • COLL 1.25
  • Revenue
  • ARDX $361,706,000.00
  • COLL $664,283,000.00
  • Revenue This Year
  • ARDX $12.01
  • COLL $20.04
  • Revenue Next Year
  • ARDX $34.66
  • COLL $3.98
  • P/E Ratio
  • ARDX N/A
  • COLL $24.19
  • Revenue Growth
  • ARDX 127.33
  • COLL 17.17
  • 52 Week Low
  • ARDX $3.21
  • COLL $23.23
  • 52 Week High
  • ARDX $7.18
  • COLL $42.29
  • Technical
  • Relative Strength Index (RSI)
  • ARDX 63.34
  • COLL 54.25
  • Support Level
  • ARDX $3.49
  • COLL $29.28
  • Resistance Level
  • ARDX $4.34
  • COLL $30.83
  • Average True Range (ATR)
  • ARDX 0.17
  • COLL 0.75
  • MACD
  • ARDX 0.08
  • COLL -0.00
  • Stochastic Oscillator
  • ARDX 82.35
  • COLL 51.63

About ARDX Ardelyx Inc.

Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.

About COLL Collegium Pharmaceutical Inc.

Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.

Share on Social Networks: